Premium
Sparfloxacin: Potential Clinical and Economic Impact in the Treatment of Respiratory Infections
Author(s) -
Stein Gary E.,
Havlichek Daniel H.
Publication year - 1997
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1002/j.1875-9114.1997.tb03079.x
Subject(s) - sparfloxacin , respiratory system , intensive care medicine , medicine , antibiotics , microbiology and biotechnology , biology , ofloxacin , ciprofloxacin
Sparfloxacin is a new oral fluoroquinolone antimicrobial that is highly active against common respiratory pathogens, including multiresistant strains. It is well absorbed and has excellent penetration into upper and lower respiratory tissues. Sparfloxacin is administered once a day and does not interfere with the metabolism of other drugs. The agent is highly effective and safe in the treatment of acute sinusitis, exacerbations of chronic bronchitis, and community‐acquired pneumonia. Due to its activity against multidrug‐resistant respiratory pathogens, it has the potential to prevent hospitalization as well as decrease parenteral antibiotic therapy. Consequently, it may generate significant pharmacoeconomic benefits to patients and payers of medical care.